Skip to content
Serodus
  • About Serodus
    • Board of directors
    • Management
    • Former Advisors
  • Pipeline
    • SER130
    • SER140
    • SER150
    • Diabetic Kidney Disease
  • OPEN FOR ACQUISITION
  • Investor
    • Financial Calendar
    • Quarterly Reports
    • Annual Reports
    • General Meeting
    • Article of Association
    • Corporate governance
  • News
  • Contact
  • Toggle website search
Press Escape to close the search panel.
Menu Close

2023-06 – Investor Meeting in Copenhagen

  • Post author:Henrik Mordhorst
  • Post published: 09-06-2023
  • Post category:News

Address: Stokholmsgade 412100 Copenhagen E June 21, 2023, at 15:00Please reserve the date

Continue Reading2023-06 – Investor Meeting in Copenhagen

2023-05 – Serodus AS – Minutes of Annual General Meeting 2023

  • Post author:Henrik Mordhorst
  • Post published: 31-05-2023
  • Post category:News

Download the minutes here

Continue Reading2023-05 – Serodus AS – Minutes of Annual General Meeting 2023

2023-05 – Serodus ASA – Notice of General Meeting 2023

  • Post author:Henrik Mordhorst
  • Post published: 16-05-2023
  • Post category:News

Read more here Norwegian VPS registred shareholders: VPS General Meeting

Continue Reading2023-05 – Serodus ASA – Notice of General Meeting 2023

2023-05 – 2022 Annual Report

  • Post author:Henrik Mordhorst
  • Post published: 11-05-2023
  • Post category:News

Serodus ASA - Publishes 2022 Annual Report Download it here

Continue Reading2023-05 – 2022 Annual Report

2023-04 – Q1 2023 Reporting

  • Post author:Henrik Mordhorst
  • Post published: 27-04-2023
  • Post category:News

Serodus has visited all clinical centers in Australia and New Zealand SER150/placebo dosing period has been prolonged from 3 to 6 months. Read more here

Continue Reading2023-04 – Q1 2023 Reporting

2022-10 – Q3 2022 Reporting

  • Post author:Henrik Mordhorst
  • Post published: 31-10-2022
  • Post category:News

Transition to the new Australian based CRO was finalized during Q3.Australian ethical committee has approved increasing dosing period from 3 to 6 months.Reactivation of Australian centers by the new CRO.Centers…

Continue Reading2022-10 – Q3 2022 Reporting

2022-10 – European Patent office has Published a SER150 patent 19th October 2022

  • Post author:Henrik Mordhorst
  • Post published: 24-10-2022
  • Post category:News

European Patent office has Published a SER150 patent 19th October 2022Download

Continue Reading2022-10 – European Patent office has Published a SER150 patent 19th October 2022

2022-08 – Q2 2022 Reporting

  • Post author:Henrik Mordhorst
  • Post published: 26-08-2022
  • Post category:News

Still low number of patients entered the study in Q2-2022.A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.Complete transfer expected to be…

Continue Reading2022-08 – Q2 2022 Reporting

2022-06 – Serodus ASA – Notice of General Meeting 2022

  • Post author:Henrik Mordhorst
  • Post published: 15-06-2022
  • Post category:News

Read more here

Continue Reading2022-06 – Serodus ASA – Notice of General Meeting 2022

2022-05 – Serodus ASA – Notice of postponement

  • Post author:Henrik Mordhorst
  • Post published: 20-05-2022
  • Post category:News

AGM 2022 to be postponed until late june 2022 Read more

Continue Reading2022-05 – Serodus ASA – Notice of postponement
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • Go to the next page

Serodus AS

Heia 8
N-0268 Oslo
Norway

Contact us

News

Sign up below to receive our newsletters.
Close Menu
  • About Serodus
    • Board of directors
    • Management
    • Former Advisors
  • Pipeline
    • SER130
    • SER140
    • SER150
    • Diabetic Kidney Disease
  • OPEN FOR ACQUISITION
  • Investor
    • Financial Calendar
    • Quarterly Reports
    • Annual Reports
    • General Meeting
    • Article of Association
    • Corporate governance
  • News
  • Contact
  • Toggle website search
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT